Reata Pharmaceuticals
OverviewSuggest Edit
Reata Pharmaceuticals is a biopharmaceutical company that develops therapeutics for patients with serious or life-threatening diseases. It targets molecular pathways involved in the regulation of cellular metabolism and inflammation. Reata’s two clinical candidates, bardoxolone methyl and omaveloxolone, target the important transcription factor Nrf2 to restore mitochondrial function, reduce oxidative stress, and resolve inflammation.
| Type | Public | |
| Founded | 2002 | |
| HQ | Plano, TX, US | Map |
| Website | reatapharma.com | |
| Employee Ratings | More | |
| Overall Culture | B | More |
Recent NewsAll News
- Reata Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2020 Financial Results and Provides an Update on Clinical Development Programs
- Reata Pharmaceuticals, Inc. to Report Fourth Quarter and Full Year 2020 Financials and to Provide an Update on Development Programs on March 1, 2021
- Reata Pharmaceuticals, Inc. Announces Pricing of Class A Common Stock Offering
- Reata Pharmaceuticals, Inc. Announces Proposed Public Offering of Class A Common Stock
Key People/Management at Reata Pharmaceuticals
Warren Huff
Founding Chief Executive Officer and President, Director
Dawn C. Bir
Chief Commercial Officer and Executive Vice President
Colin Meyer
Chief Research & Development Officer and Executive Vice President
Manmeet S. Soni
Chief Operating Officer & Chief Financial Officer and Executive Vice President
Michael D. Wortley
Chief Legal Officer and Executive Vice President
Joel Proksch
Senior Vice President, Chief Development Operations Officer
Reata Pharmaceuticals Office Locations
Reata Pharmaceuticals has offices in Plano and Irving
Plano, TX, US (HQ)
5320 Legacy Dr
Irving, TX, US
2801 Gateway Dr #150
Plano, TX, US
5340 Legacy Dr
Reata Pharmaceuticals Financials and Metrics
Reata Pharmaceuticals Revenue
Reata Pharmaceuticals's revenue was reported to be $9.02 m in FY, 2020
| USD | |
|---|---|
Revenue (FY, 2020) | 9.0m |
Net income (FY, 2020) | (247.8m) |
Market capitalization (30-Mar-2021) | 3.5b |
Closing stock price (30-Mar-2021) | 97.1 |
Cash (31-Dec-2020) | 818.2m |
Reata Pharmaceuticals's current market capitalization is $3.5 b.
Annual
Quarterly
| USD | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 | Q3, 2020 |
|---|---|---|---|---|---|---|---|---|---|
Revenue | 32.4m | 7.6m | 5.2m | 7.8m | 7.8m | 8.2m | 1.4m | 3.1m | 1.4m |
General and administrative expense | 6.6m | 10.7m | 7.5m | 10.0m | 11.7m | 14.3m | 20.8m | 16.6m | 18.3m |
R&D expense | 21.4m | 23.4m | 27.1m | 26.1m | 29.6m | 32.3m | 47.7m | 36.8m | 37.2m |
Operating expense total | 28.1m | 34.2m | 34.7m | 36.3m | 41.5m | 46.8m | 68.7m | 53.7m | 55.8m |
Annual
Quarterly
Annual
Quarterly
| USD | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 | Q3, 2020 |
|---|---|---|---|---|---|---|---|---|---|
Net Income | 4.1m | (24.1m) | (55.0m) | (29.2m) | (63.5m) | (103.2m) | (48.9m) | (116.5m) | (182.0m) |
Depreciation and Amortization | 101.0k | 206.0k | 311.0k | 170.0k | 401.0k | 659.0k | 278.0k | 562.0k | 851.0k |
Accounts Payable | (1.1m) | 46.0k | 2.9m | (522.0k) | 312.0k | (440.0k) | 10.7m | 9.4m | 7.0m |
Cash From Operating Activities | (24.0m) | (49.4m) | (46.3m) | (28.7m) | (61.4m) | (101.8m) | (41.2m) | (237.1m) | (277.2m) |
| USD | FY, 2017 |
|---|---|
Revenue/Employee | 516.8k |
Debt/Equity | -0.1 x |
Debt/Assets | 0.1 x |
Financial Leverage | -0.9 x |
Reata Pharmaceuticals Operating Metrics
| FY, 2016 | |
|---|---|
Patents Issued | 240 |
Patents Pending | 280 |
Phase I Trials Products | 2 |
Phase III Trials Products | 1 |
Reata Pharmaceuticals Revenue Breakdown
Reata Pharmaceuticals revenue breakdown by business segment: 95.3% from License and Milestone and 4.7% from Other
Reata Pharmaceuticals Cybersecurity Score
Reata Pharmaceuticals Environment, Social & Governance (ESG) Ratings
Reata Pharmaceuticals Online and Social Media Presence
1.1k Twitter followers
Reata Pharmaceuticals has 1.1k Twitter Followers. The number of followers has increased 2.5% month over month and increased 8.7% quarter over quarter
Reata Pharmaceuticals's Trends
Twitter Engagement Stats for @ReataPharma
945
Tweets
506
Following
1.1k
Followers
22
Tweets last 30 days
6
Avg. likes per Tweet
100%
Tweets with engagement
Reata Pharmaceuticals Company Culture
Overall Culture
B
81/100
CEO Rating
A-
80/100
Compensation
A+
95/100
Reata Pharmaceuticals News and Updates
March 01, 2021
Reata Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2020 Financial Results and Provides an Update on Clinical Development Programs
ANNOUNCES FIRST NDA SUBMISSION FOR COMPANY’S LEAD PROGRAM: BARDOXOLONE IN ALPORT SYNDROME
February 22, 2021
Reata Pharmaceuticals, Inc. to Report Fourth Quarter and Full Year 2020 Financials and to Provide an Update on Development Programs on March 1, 2021
PLANO, Texas, Feb. 22, 2021 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” or “we”), a clinical-stage biopharmaceutical company, today announced that it will report financial results and provide an update on recent progress on its development programs pre-m…
December 02, 2020
Reata Pharmaceuticals, Inc. Announces Pricing of Class A Common Stock Offering
Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata” or the “Company”), a clinical-stage biopharmaceutical company, today announced that it has priced a public offering of 2,000,000 shares by the Company of its Class A common stock at a price to the public of $140.85 per share, for gross proceeds of …
December 01, 2020
Reata Pharmaceuticals, Inc. Announces Proposed Public Offering of Class A Common Stock
Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata” or the “Company”), a clinical-stage biopharmaceutical company, today announced the launch of a proposed underwritten public offering by the Company of 2,000,000 shares of its Class A common stock pursuant to an existing shelf registration statement…
November 09, 2020
Reata Pharmaceuticals, Inc. Announces Third Quarter 2020 Financial Results and Provides an Update on Business Operations and Clinical Development Programs
Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” or “we”), a clinical-stage biopharmaceutical company, today announced financial results for the quarter ended September 30, 2020, and provided an update on the Company’s business operations and clinical development programs.
October 16, 2020
Pomerantz Law Firm Announces the Filing of a Class Action against Reata Pharmaceuticals, Inc. and Certain Officers - RETA
Pomerantz LLP announces that a class action lawsuit has been filed against Reata Pharmaceuticals, Inc. ("Reata" or the "Company") (NASDAQ: RETA) and certain of its officers. The class action, filed in United States District Court for the Eastern
Reata Pharmaceuticals Blogs
November 02, 2020
Reata Pharmaceuticals, Inc. to Report Third Quarter 2020 Financial Results and Provide an Update on Development Programs on November 9, 2020
Reata Pharmaceuticals, Inc. to Report Third Quarter 2020 Financial Results and Provide an Update on Development Programs on November 9, 2020
Content Import
Mon, 11/02/2020 - 17:30
Reata Pharmaceuticals, Inc. to Report Third Quarter 2020 Financial Results and Provide an Update on Developmen…
October 26, 2020
Reata Announces Publication of Results From Pivotal Moxie Trial of Omaveloxolone in Patients with Friedreich’s Ataxia
PLANO, Texas , Oct. 26, 2020 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” or “we”), a clinical-stage biopharmaceutical company, today announced that results from the pivotal part 2 portion of the MOXIe trial evaluating the efficacy and safety of
July 30, 2020
Reata Announces the Appointment of Martin W. Edwards, M.D. to Its Board of Directors
PLANO, Texas , July 30, 2020 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” or “we”), a clinical-stage biopharmaceutical company, today announced the appointment of Martin W. Edwards , M.D. to its Board of Directors, effective August 3, 2020 . Since 2003,
May 11, 2020
Reata Pharmaceuticals, Inc. Announces First Quarter 2020 Financial Results and Provides an Update on Development Programs
Reata Pharmaceuticals, Inc. Announces First Quarter 2020 Financial Results and Provides an Update on Development Programs
Content Import
Mon, 05/11/2020 - 16:02
Reata Pharmaceuticals, Inc. Announces First Quarter 2020 Financial Results and Provides an Update on Development Programs
…
May 04, 2020
Reata Pharmaceuticals, Inc. to Report First Quarter 2020 Financial Results and to Provide an Update on Development Programs on May 11, 2020
Reata Pharmaceuticals, Inc. to Report First Quarter 2020 Financial Results and to Provide an Update on Development Programs on May 11, 2020
Content Import
Mon, 05/04/2020 - 16:36
Reata Pharmaceuticals, Inc. to Report First Quarter 2020 Financial Results and to Provide an Update on Developm…
March 30, 2020
Reata Pharmaceuticals Provides Update on the Impact of the COVID-19 Pandemic on Its Clinical Studies and Business Operations
Reata Pharmaceuticals Provides Update on the Impact of the COVID-19 Pandemic on Its Clinical Studies and Business Operations
Content Import
Mon, 03/30/2020 - 16:06
Reata Pharmaceuticals Provides Update on the Impact of the COVID-19 Pandemic on Its Clinical Studies and Business Operations
…
Reata Pharmaceuticals Frequently Asked Questions
When was Reata Pharmaceuticals founded?
Reata Pharmaceuticals was founded in 2002.
Who are Reata Pharmaceuticals key executives?
Reata Pharmaceuticals's key executives are Warren Huff, Dawn C. Bir and Colin Meyer.
How many employees does Reata Pharmaceuticals have?
Reata Pharmaceuticals has 220 employees.
What is Reata Pharmaceuticals revenue?
Latest Reata Pharmaceuticals annual revenue is $9 m.
What is Reata Pharmaceuticals revenue per employee?
Latest Reata Pharmaceuticals revenue per employee is $41 k.
Who are Reata Pharmaceuticals competitors?
Competitors of Reata Pharmaceuticals include Apellis Pharmaceuticals, Alnylam Pharmaceuticals and Ionis Pharmaceuticals.
Where is Reata Pharmaceuticals headquarters?
Reata Pharmaceuticals headquarters is located at 5320 Legacy Dr, Plano.
Where are Reata Pharmaceuticals offices?
Reata Pharmaceuticals has offices in Plano and Irving.
How many offices does Reata Pharmaceuticals have?
Reata Pharmaceuticals has 3 offices.
Learn about Craft real-time company insights
Receive alerts for 300+ data fields across thousands of companies